ClinicalTrials.gg
Active, not recruitingNCT05526755TARGETUpdated Aug 3, 2026

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

A Phase 2 interventional study of Osimertinib 80 mg/40 mg in Stage II-IIIB Non-small Cell Lung Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 56 sites in 11 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
18th of 90
188 · median 51
Started
2023
with 3 others
Phase 2
46 of 90
12 open now
Primary completion
2029-11
later than 41 of 42 live
Registered
73rd of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 18th largest by enrollment, is one of 4 that started in 2023, is one of 46 in phase 2, reaches primary completion later than 41 of the 42 other live ones, and was the 73rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.

Read the detailed description

This is a phase 2 open-label study to assess the efficacy and safety of osimertinib in participants with stage II-IIIB NSCLC with sensitising EGFR mutations. The study is designed to evaluate 5 years of adjuvant osimertinib therapy.

03

Conditions studied

  • Stage II-IIIB Non-small Cell Lung Carcinoma

Keywords

  • Stage II-IIIB Non-small Cell Lung Cancer
  • Adjuvant osimertinib
  • Adjuvant chemotherapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged at least 18 years.
  2. confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
  3. Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.
  4. Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.
  5. Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).
  6. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
  7. Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.
  8. World Health Organisation Performance Status of 0 to 1.
  9. Female participants must be using highly effective measures, and must have a negative pregnancy test prior to start of dosing if of .
  10. Male participants must use effective barrier contraception.

Exclusion criteria

Exclusion Criteria:

  1. Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.
  2. Participants currently receiving medications or herbal supplements known to be strong inducers of (at least 3 weeks prior to first dose).
  3. Participants who have had only segmentectomies or wedge resections.
  4. History of other , except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years before the start of study intervention.
  5. Treatment with any of the following:

    • Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
    • Pre-operative () platinum-based or other chemotherapy.
    • Any prior anti-cancer or immunological therapy, including therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.
    • Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).
  6. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  7. Any of the following cardiac criteria:

    • Mean resting (QTc) interval > 470 msec, obtained from 3 (ECGs).
    • Any abnormalities in rhythm, conduction, or morphology of resting ECG.
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
    • Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).
  8. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required treatment, or any evidence of clinically active ILD.
  9. Inadequate bone marrow reserve or organ function.
  10. Women who are breastfeeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Osimertinib

    Participants will receive osimertinib (AZD9291).

    Drug: Osimertinib 80 mg/40 mg

Interventions

  • DrugOsimertinib 80 mg/40 mg

    Drug page: Osimertinib

    Participants will receive osimertinib (80 mg or 40 mg orally, once daily).

    Also known as: AZD9291, TAGRISSO™

06

What researchers measure

Primary outcomes

  1. Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].

    Defined as time from date of first dose until disease recurrence, or death due to any cause in the absence of recurrence.

    Time frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years.

Secondary outcomes

  1. Disease Free Survival Rate at 3, 4 and 5 Years (Uncommon EGFRm Cohort)

    Defined as the proportion of participants alive and disease free at 3, 4, and 5 years.

    Time frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.

  2. DFS Rate at 3 and 4 Years (Common EGFRm Cohort)

    Defined as the proportion of participants alive and disease free at 3, and 4 years.

    Time frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, and 4 years.

  3. Overall Survival (OS) [Common EGFRm Cohort]

    Defined as time from date of first dose until the date of death due to any cause.

    Time frame: From date of first dose until the date of death due to any cause, up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.

  4. Safety and tolerability in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)

    Adverse Events (AEs) graded by CTCAE version 5.0.

    Time frame: From date of first dose up to approximately 5 years

  5. Recurrence events in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)

    Local/regional, or distant recurrence events assessed.

    Time frame: From date of first dose up to approximately 5 years

07

Study locations

56 sites
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Las Vegas, Nevada 89169, United States
  • Research Site
    White Plains, New York 10601, United States
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Avellino, 83100, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Lecce, 73100, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Palermo, 90146, Italy
  • Research Site
    Peschiera del Garda, 37019, Italy
  • Research Site
    Reggio Emilia, 42123, Italy
  • Research Site
    Sondrio, 23100, Italy
  • Research Site
    Terni, 05100, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuantan, 25100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Cebu, 6000, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Quezon City, 1100, Philippines
  • Research Site
    Singapore, 119074, Singapore
  • Research Site
    Busan, 48108, South Korea
  • Research Site
    Busan, 49241, South Korea
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Daejeon, 35015, South Korea
  • Research Site
    Goyang-si, 410-769, South Korea
  • Research Site
    Gyeonggi-do, 13620, South Korea
  • Research Site
    Incheon, 21565, South Korea
  • Research Site
    Seongnam-si, 13496, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05030, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06273, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Badalona, 08013, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Bilbao, 48013, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Hualien City, 970, Taiwan
  • Research Site
    Kaohsiung City, 82445, Taiwan
  • Research Site
    Kaohsiung City, 833401, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 10449, Taiwan
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Songkhla, 90110, Thailand
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
08

References and documents

Publications

  • Soo RA, de Marinis F, Han JY, Ho JC, Martin E, Servidio L, Sandelin M, Popat S. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection. Clin Lung Cancer. 2024 Jan;25(1):80-84. doi: 10.1016/j.cllc.2023.09.005. Epub 2023 Oct 4. PubMed 37914594 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2029, 80 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 80 months is above that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2022
First posted
Sep 2, 2022
StartActual
Mar 6, 2023
Primary completionEst.
Nov 22, 2029
CompletionEst.
Nov 22, 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05526755
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Mar 6, 2023
Primary completion
Nov 22, 2029 (estimated)
Completion
Nov 22, 2029 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion